Mersana reports Phase I data for XMT-1522 in HER2-expressing cancers

Mersana Therapeutics Inc. (NASDAQ:MRSN) reported interim data from 19 patients with advanced HER2-expressing breast, gastric or non-small cell

Read the full 181 word article

User Sign In